Literature DB >> 15634936

Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans.

Markus Huber-Lang1, J Vidya Sarma, Daniel Rittirsch, Heike Schreiber, Manfred Weiss, Michael Flierl, Ellen Younkin, Marion Schneider, Heidemarie Suger-Wiedeck, Florian Gebhard, Shannon D McClintock, Thomas Neff, Firas Zetoune, Uwe Bruckner, Ren-Feng Guo, Peter N Monk, Peter A Ward.   

Abstract

Sepsis is associated with extensive complement activation, compromising innate immune defenses, especially in neutrophils (PMN). Recently, a second C5a receptor (C5L2) was detected on PMN without evidence of intracellular signaling. The current study was designed to determine changes in C5L2 in blood PMN during sepsis. In vitro exposure of PMN to C5a, but not to fMLP, led to reduced content of C5L2. Following cecal ligation and puncture-induced sepsis in rats, PMN demonstrated a time-dependent decrease in C5L2. In vivo blockade of C5a during experimental sepsis resulted in preservation of C5L2. Similarly, PMN from patients with progressive sepsis showed significantly reduced C5L2 expression (n = 26), which was virtually abolished in patients who developed multiorgan failure (n = 10). In contrast, sepsis survivors exhibited retention of C5L2 (n = 12/13). The data suggest that C5L2 on PMN diminishes during sepsis due to systemic generation of C5a, which is associated with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634936     DOI: 10.4049/jimmunol.174.2.1104

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Complement 5a receptor-mediated neutrophil dysfunction is associated with a poor outcome in sepsis.

Authors:  Ruonan Xu; Fang Lin; Chunmei Bao; Huihuang Huang; Chengcheng Ji; Siyu Wang; Lei Jin; Lijian Sun; Ke Li; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2015-03-02       Impact factor: 11.530

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 3.  Harmful molecular mechanisms in sepsis.

Authors:  Daniel Rittirsch; Michael A Flierl; Peter A Ward
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

4.  Genetic analysis of C5a receptors in neutrophils from patients with familial Mediterranean fever.

Authors:  Eirini Apostolidou; Konstantinos Kambas; Akrivi Chrysanthopoulou; Ioannis Kourtzelis; Matthaios Speletas; Konstantinos Ritis; Ioannis Mitroulis
Journal:  Mol Biol Rep       Date:  2011-12-21       Impact factor: 2.316

5.  Functional roles for C5a receptors in sepsis.

Authors:  Daniel Rittirsch; Michael A Flierl; Brian A Nadeau; Danielle E Day; Markus Huber-Lang; Charles R Mackay; Firas S Zetoune; Norma P Gerard; Katherine Cianflone; Jörg Köhl; Craig Gerard; J Vidya Sarma; Peter A Ward
Journal:  Nat Med       Date:  2008-05-04       Impact factor: 53.440

6.  Delayed cerebral thrombosis in bacterial meningitis: a prospective cohort study.

Authors:  Marjolein J Lucas; Matthijs C Brouwer; Diederik van de Beek
Journal:  Intensive Care Med       Date:  2012-12-18       Impact factor: 17.440

Review 7.  Functions of C5a receptors.

Authors:  Peter A Ward
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

Review 8.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

9.  Complement and neutrophil function changes after liver resection in humans.

Authors:  Christoph Werner Strey; Britta Siegmund; Saskia Rosenblum; Rosa Maria Marquez-Pinilla; Elsie Oppermann; Markus Huber-Lang; John D Lambris; Wolf O Bechstein
Journal:  World J Surg       Date:  2009-12       Impact factor: 3.352

Review 10.  Sepsis and immune response.

Authors:  Xing-Hai Chen; Yong-Jie Yin; Jing-Xiao Zhang
Journal:  World J Emerg Med       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.